Summary of Significant Accounting Policies - Segments (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Medical Indication Information
Number of reportable segments | segment			1
Total net sales	$ 80,507	$ 78,357	$ 236,480	$ 266,390
Analgesic
Medical Indication Information
Total net sales	2,741	3,292	8,757	12,525
Anti-Psychosis
Medical Indication Information
Total net sales	2,082	3,346	7,277	9,156
Cardiovascular
Medical Indication Information
Total net sales	13,059	9,468	37,030	33,321
Central Nervous System
Medical Indication Information
Total net sales	19,311	15,177	61,887	60,302
Endocrinology
Medical Indication Information
Total net sales	8,066	6,792	21,209	22,934
Gastrointestinal
Medical Indication Information
Total net sales	9,932	11,709	26,590	40,972
Infectious Disease
Medical Indication Information
Total net sales	2,826	5,438	12,884	24,473
Migraine
Medical Indication Information
Total net sales	2,768	3,507	9,666	12,638
Respiratory/Allergy/Cough/Cold
Medical Indication Information
Total net sales	981	2,309	3,651	7,291
Other
Medical Indication Information
Total net sales	13,342	14,700	33,056	35,327
Contract manufacturing revenue
Medical Indication Information
Total net sales	$ 5,399	$ 2,619	$ 14,473	$ 7,451